Emergent BioSolutions Inc.
EBS
$8.71
-$0.49-5.33%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 95.76% | 655.56% | 36.77% | 143.58% | -8.30% |
| Total Depreciation and Amortization | -17.54% | -8.96% | -12.16% | -5.71% | -13.37% |
| Total Amortization of Deferred Charges | -52.00% | -66.67% | -61.40% | -217.54% | -43.82% |
| Total Other Non-Cash Items | -103.51% | 232.58% | 142.86% | -120.72% | -63.23% |
| Change in Net Operating Assets | -53.52% | -21.74% | -299.30% | -0.30% | 244.19% |
| Cash from Operations | 124.00% | 82.11% | -348.91% | 156.17% | 141.52% |
| Capital Expenditure | 36.96% | 66.67% | 85.09% | 53.97% | 63.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 473.91% | 650.93% | 350.88% | 692.59% | -101.79% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -862.70% | 87.81% |
| Issuance of Common Stock | 0.00% | -- | 14.29% | -- | -92.63% |
| Repurchase of Common Stock | -3,450.00% | -25.00% | -200.00% | -200.00% | 0.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 87.43% | -100.98% | -89.36% | -319.30% | 89.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,577.50% | 244.34% | -312.55% | 10,775.00% | 97.66% |